Featured Publications
Oropharyngeal Cancer Early Outcomes and Challenges During the COVID-19 Pandemic
Kang J, Wu Y, Rybkin A, Yu Y, Chen L, Zakeri K, McBride S, Riaz N, Tsai C, Gelblum D, Wong R, Sherman E, Pfister D, Lee N. Oropharyngeal Cancer Early Outcomes and Challenges During the COVID-19 Pandemic. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e412. PMCID: PMC8536212, DOI: 10.1016/j.ijrobp.2021.07.1185.Peer-Reviewed Original ResearchDefinitive radiation therapyCOVID cohortRadiation therapyMore patientsAdvanced diseaseMonth outcomesPC cohortNew patientsCurative-intent radiation therapyGrade 3 dysphagiaOropharyngeal cancer outcomesCancer-specific survivalSupportive care needsKaplan-Meier methodLong-term outcomesDiagnosis/treatmentCOVID-19 pandemicMATERIAL/METHODSPerson consultsRT startClinicopathologic factorsOPC patientsHistorical cohortMedian timeEarly outcomesDose and Volume De-Escalation for Elective Nodal Regions in Patients With Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer (OPC) Undergoing Curative-Intent Concurrent Chemoradiation (CCRT)
Tsai C, McBride S, Riaz N, Kang J, Spielsinger D, Waldenberg T, Yu Y, Chen L, Zakeri K, Wong R, Dunn L, Sherman E, Lee N. Dose and Volume De-Escalation for Elective Nodal Regions in Patients With Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer (OPC) Undergoing Curative-Intent Concurrent Chemoradiation (CCRT). International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s142-s143. DOI: 10.1016/j.ijrobp.2021.07.321.Peer-Reviewed Original ResearchConcurrent chemoradiationDe-escalation strategiesOropharyngeal cancerGross diseaseNodal recurrenceDisease recurrenceOPC patientsLevel IbHPV-positive OPC patientsLocoregional recurrence-free survivalElective nodal regionsFavorable locoregional controlFeeding tube dependenceHigh-dose cisplatinPositive oropharyngeal cancerPrimary concurrent chemoradiationRecurrence-free survivalNode-positive neckFeeding tube placementLong-term resultsNode-negative neckDe-escalation approachMATERIAL/METHODSHigh control ratesRadiation treatment plans
2022
Peer Review of Head and Neck Cancer Planning Target Volumes in Radiation Oncology
Hesse J, Zakeri K, Chen L, Yu Y, Kang J, Riaz N, Tsai C, McBride S, Gelblum D, Lee N. Peer Review of Head and Neck Cancer Planning Target Volumes in Radiation Oncology. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e472-e473. DOI: 10.1016/j.ijrobp.2022.07.1729.Peer-Reviewed Original ResearchStart of RTTarget volumeFurther workupNeck cancerTreatment planPositive findingsNeck radiation oncologistMinority of patientsOverall treatment planTreatment planningPlanning target volumeProspective peer reviewTumor board discussionMATERIAL/METHODSNeck cancer casesRadiation treatment plansFurther surgeryUnderwent biopsyAdditional surgeryAdditional workupOncology servicesSignificant changesCancer casesPatientsRadiation oncologistsTreatment Outcomes for Radiation Therapy with Concurrent Carboplatin and Paclitaxel for Locally Advanced Head and Neck Cancer
Han J, Zakeri K, Raab G, Chen L, Yu Y, Kang J, McBride S, Riaz N, Tsai C, Gelblum D, Sherman E, Wong R, Michel L, Lee N. Treatment Outcomes for Radiation Therapy with Concurrent Carboplatin and Paclitaxel for Locally Advanced Head and Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e317. DOI: 10.1016/j.ijrobp.2022.07.1381.Peer-Reviewed Original ResearchProgression-free survivalCisplatin-ineligible patientsDefinitive radiation therapyUnknown primary cancerLocoregional controlRadiation therapyDistant controlConcurrent carboplatinWeekly carboplatinAdvanced headOverall survivalHNSCC patientsPrimary cancerNeck squamous cell carcinomaConclusions Radiation therapyConsecutive HNSCC patientsCycles of chemotherapySevere ulcerative colitisUpper gastrointestinal bleedMedian radiation doseSynchronous primary malignanciesKaplan-Meier methodSquamous cell carcinomaMATERIAL/METHODSCumulative incidence functionPhysician Graded Toxicity Profiles and Survival Outcomes among Patients with Non-Metastatic Oropharyngeal Carcinoma Treated with Proton Therapy vs. Intensity-Modulated Radiation Therapy
Youssef I, Yoon J, Zakeri K, Cohen M, Wong R, Yu Y, Kang J, Gelblum D, McBride S, Sherman E, Dunn L, Cracchiolo J, Chen L, Lee N. Physician Graded Toxicity Profiles and Survival Outcomes among Patients with Non-Metastatic Oropharyngeal Carcinoma Treated with Proton Therapy vs. Intensity-Modulated Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e325-e326. DOI: 10.1016/j.ijrobp.2022.07.1399.Peer-Reviewed Original ResearchProgression-free survivalIntensity-modulated radiation therapyOropharyngeal carcinomaAcute gradeIMRT groupLocoregional recurrenceOncologic outcomesAdverse eventsOverall survivalRadiation therapyPT groupSignificant differencesTreatment-related adverse eventsPatient/tumor characteristicsProton therapyCurative-intent radiationGrade 3 dysphagiaPresence of xerostomiaMedian RT doseRetrospective cohort studyProspective Randomized ComparisonPatient-reported outcomesSimilar oncologic outcomesMATERIAL/METHODSReduction of dose